Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression

详细信息    查看全文

• 作者：Marina A. Gruden^a ; Robert D.E. Sewell^b ; ^{sewell@cardiff.ac.uk} ; Kiran Yanamandra^c ; Tatyana V. Davidova^d ; Valery G. Kucheryanu^d ; Evgeny V. Bocharov^d ; Olga R. Bocharova^e ; Vsevolod V. Polyschuk^f ; Vladimir V. Sherstnev^a ; Ludmilla A. Morozova-Roche^c
• 关键词：Parkinson's disease ; α ; -synuclein ; amyloid toxicity ; autoantibodies ; T-cells ; B-cells
• 刊名：Journal of Neuroimmunology
• 出版年：2011
• 出版时间：April 2011
• 年：2011
• 卷：233
• 期：1-2
• 页码：221-227
• 全文大小：842 K

文摘

The aim was to ascertain any possible linkage between humoral immune responses to principal biomarkers (α-synuclein monomers, its toxic oligomers or fibrils, dopamine and S100B) and cellular immunity in Parkinson's disease development. There were elevated autoantibody titers to α-synuclein monomers, oligomers plus fibrils in 72 % , 56 % , and 17 % of Parkinsonian patients respectively with a 5-year disease duration. Additionally, there were increased titers to dopamine and S100B (96 % and 89 % ) in the 5-year patient group. All of these values subsided in 10-year sufferers.

Furthermore, CD3+, CD4+, CD8+ T-lymphocyte and B-lymphocyte subsets declined in the patient cohort during Parkinsonism indicating disease associated reductions in these lymphocyte subsets.